Fort Smith, Arkansas 72916

  • Human Papilloma Virus

Purpose:

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).


Study summary:

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at either 0.3 mL dose levels at up to 6 monthly injections (a maximal, cumulative dose of 1.9 mL, including the delayed-type hypersensitivity (DTH) test) for treating common warts (Verruca vulgaris). A secondary objective is to understand the relative effectiveness of the 0.3 dose level for treating common warts, both those that were injected and those that were not injected as well as other types of warts that were not injected to allow a determination of appropriate dose levels to use in a future dose-ranging efficacy trial.


Criteria:

Inclusion Criteria: - Must have at least 3 and not more than 10 common warts not located on the palms or digits - Positive DTH response to Candin® required Exclusion Criteria: - No previous medical treatment for warts other than OTC - No immunocompromising medical conditions or medicines allowed - No preexisting inflammatory conditions at treatment site allowed


NCT ID:

NCT01757392


Primary Contact:

Principal Investigator
Sandy M Johnson, MD
Johnson Dermatology


Backup Contact:

N/A


Location Contact:

Fort Smith, Arkansas 72916
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.